Impact of COVID-19 on work loss in the United States- A retrospective database analysis
Authors:
- Jennifer JudyJJJennifer Judy
- Alon YehoshuaAYAlon Yehoshua
- Julie Gouveia-PisanoJGJulie Gouveia-Pisano
- Richard A. BrookRBRichard A. Brook
- Nathan L. KleinmanNKNathan L. Kleinman
- Alek A. DrnachADAlek A. Drnach
- Eric M. RosenbergEREric M. Rosenberg
- Tanya GhanjanasakTGTanya Ghanjanasak
- Deborah A. WinterDWDeborah A. Winter
- Feng DaiFDFeng Dai
- Jannette M. EscobarJEJannette M. Escobar
- Heather SellHSHeather Sell
Open Access
- 18 July 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 27 (1) , 941-951
Abstract
ObjectivesThis study investigates the utilization of work absence benefits among United States (US) employees diagnosed with COVID-19, examining frequency, duration, cost, and types of work loss benefits used.MethodsThis retrospective analysis of the Workpartners Research Reference Database (RRDb) included employees eligible for short- and long-term disability (STD and LTD employer-sponsored benefits, respectively), and other paid work absence benefits from 2018-2022. Workpartners RRDb includes over 3.5 million employees from over 500 self-insured employers across the US. Employees were identified by codes from adjudicated medical and disability claims for COVID-19 (2020-2022) and influenza, as well as prescription claims for COVID-19. Associated payments were quantified for each absence reason.ResultsApproximately 1 million employees were eligible for employer-sponsored paid leave benefits between January 2018 and December 2022. The mean age was 37 years (22% >50 years), and 49.9% were female. COVID-19 was the 2nd most common reason for an STD claim (6.9%) and 13th for an LTD claim (2020-2022). The mean duration for COVID-19 STD claims was 24 days (N = 3731, mean claim=$3477) versus 10 days for influenza (N = 283, mean claim=$1721). The mean duration for an LTD claim for COVID-19 was 153 days (N = 24, mean claim=$19,254). Only 21.5% of employees with STD claims in the COVID-19 cohort had prior COVID-19-associated medical or pharmacy claims; over half (range 53%-61%) had documented high risk factors for severe COVID-19.ConclusionCOVID-19 and influenza have the potential to cause work loss in otherwise healthy employees. In this analysis, COVID-19 was the second most frequent reason for an STD claim at the start of the pandemic and remained high (ranked 5th) in 2022. These results highlight the impact of COVID-19 on work loss beyond the acute phase. Comprehensively evaluating work loss implications may help employers prioritize strategies, such as vaccinations and timely treatments, to mitigate the impact of COVID-19 on employees and their companies.Keywords
This publication has 25 references indexed in Scilit:
- Economic burden of COVID-19 for employers and employees in the United StatesJournal of Medical Economics, 2024
- Return-to-work with long COVID: An Episodic Disability and Total Worker Health® analysisSocial Science & Medicine, 2023
- Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infectionCochrane Database of Systematic Reviews, 2022
- Persistent COVID-19 symptoms in a community study of 606,434 people in EnglandNature Communications, 2022
- Post‐acute COVID‐19 syndrome (PCS) and health‐related quality of life (HRQoL)—A systematic review and meta‐analysisJournal of Medical Virology, 2021
- Characterizing long COVID in an international cohort: 7 months of symptoms and their impacteClinicalMedicine, 2021
- Face masks to prevent transmission of COVID-19: A systematic review and meta-analysisAmerican Journal of Infection Control, 2021
- Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19JAMA Network Open, 2021
- Evaluation of a SARS-CoV-2 rapid antigen test: Potential to help reduce community spread?Journal of Clinical Virology, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020